Deal Building From Testing The Water To Hitting The Market
Source: Life Science Leader
By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter
In 2017, UK-based gene and cell therapy company Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce Big Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel). The deal could be worth upwards of $100 million over its three-year span.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more